What does Arsenal Medical do?
Arsenal Medical, is a platform technology company which develops novel products which improve local therapy for diseases and injuries. This company uses conventional biomaterials in unconventional ways for developing novel products which improves the local therapy for diseases and injuries. It is advancing multiple preclinical programs based on its proprietary technology platforms- AxioCore, a novel high throughput nanofiber technology and its Therapeutic foam. Arsenal Medical is backed by venture funding and by grants from the Department of Defense, Bill & Melinda Gates Foundation and National Institute of Standards and Technology’s Technology Innovation Program.
How much Arsenal Medical was funded?
Arsenal Medical has raised $16M in Venture round on June 1, 2015 from Polaris Partners, Intersouth Partners and North Bridge Venture Partners & Growth Equity.
Previous funding
$2.1M in Debt Financing on January 20, 2010
$1M in Debt Financing on March 19, 2010
$10.1M in Venture funding on May 18, 2010
$3M in Debt Financing on August 12, 2010
$3M in Debt Financing on September 19, 2011
$3M in Debt Financing on October 4, 2012
$4M in Debt Financing on August 21, 2013
What is next for Arsenal Medical?
The company is developing 2 technology platforms, a coaxial nanofiber technology and an in situ foaming foam technology. The in situ foaming foams provides a therapy which is life saving in acute abdominal hemorrhage patients and are expected to enter the clinic later in 2015. Foams are in the process of development for other serious clinical conditions which include bleeding and vascular diseases. The nanofiber technology platform for the controlled drug delivery has entered into 2 strategic relationships recently with major pharmaceutical partners. Arsenal Medical is planning to begin human trials later in 2015, as well as nanofiber technology platform for a controlled drug delivery.
More about Arsenal Medical?
It was developed in 2005 by Carmichael Roberts and has its headquarters in Watertown, MA.